OGEN Quote, Financials, Valuation and Earnings

Galectin Therapeutics has a net margin of -- compared to Oragenics's net margin of --. Oragenics's return on equity of -- beat Galectin Therapeutics's return on equity of --.

Oragenics has a consensus price target of --, signalling upside risk potential of 24523.8%. On the other hand Galectin Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1135.82%. Given that Oragenics has higher upside potential than Galectin Therapeutics, analysts believe Oragenics is more attractive than Galectin Therapeutics.

Oragenics has a beta of 0.434, which suggesting that the stock is 56.551% less volatile than S&P 500. In comparison Galectin Therapeutics has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.07%.

Oragenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galectin Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics pays -- of its earnings as a dividend. Galectin Therapeutics pays out -- of its earnings as a dividend.

Oragenics quarterly revenues are --, which are smaller than Galectin Therapeutics quarterly revenues of --. Oragenics's net income of -$2.5M is higher than Galectin Therapeutics's net income of -$11.2M. Notably, Oragenics's price-to-earnings ratio is -- while Galectin Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics is 1.44x versus -- for Galectin Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Microbot Medical has a net margin of -- compared to Oragenics's net margin of --. Oragenics's return on equity of -- beat Microbot Medical's return on equity of --.

Oragenics has a consensus price target of --, signalling upside risk potential of 24523.8%. On the other hand Microbot Medical has an analysts' consensus of -- which suggests that it could grow by 621.58%. Given that Oragenics has higher upside potential than Microbot Medical, analysts believe Oragenics is more attractive than Microbot Medical.

Oragenics has a beta of 0.434, which suggesting that the stock is 56.551% less volatile than S&P 500. In comparison Microbot Medical has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.938%.

Oragenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics pays -- of its earnings as a dividend. Microbot Medical pays out -- of its earnings as a dividend.

Oragenics quarterly revenues are --, which are smaller than Microbot Medical quarterly revenues of --. Oragenics's net income of -$2.5M is higher than Microbot Medical's net income of -$3.2M. Notably, Oragenics's price-to-earnings ratio is -- while Microbot Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics is 1.44x versus -- for Microbot Medical. Usually stocks with elevated PS ratios are considered overvalued.

SELLAS Life Sciences Group has a net margin of -- compared to Oragenics's net margin of --. Oragenics's return on equity of -- beat SELLAS Life Sciences Group's return on equity of --.

Oragenics has a consensus price target of --, signalling upside risk potential of 24523.8%. On the other hand SELLAS Life Sciences Group has an analysts' consensus of -- which suggests that it could grow by 541.66%. Given that Oragenics has higher upside potential than SELLAS Life Sciences Group, analysts believe Oragenics is more attractive than SELLAS Life Sciences Group.

Oragenics has a beta of 0.434, which suggesting that the stock is 56.551% less volatile than S&P 500. In comparison SELLAS Life Sciences Group has a beta of 2.391, suggesting its more volatile than the S&P 500 by 139.11%.

Oragenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics pays -- of its earnings as a dividend. SELLAS Life Sciences Group pays out -- of its earnings as a dividend.

Oragenics quarterly revenues are --, which are smaller than SELLAS Life Sciences Group quarterly revenues of --. Oragenics's net income of -$2.5M is higher than SELLAS Life Sciences Group's net income of -$7.1M. Notably, Oragenics's price-to-earnings ratio is -- while SELLAS Life Sciences Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics is 1.44x versus -- for SELLAS Life Sciences Group. Usually stocks with elevated PS ratios are considered overvalued.

Alaunos Therapeutics has a net margin of -- compared to Oragenics's net margin of -28225%. Oragenics's return on equity of -- beat Alaunos Therapeutics's return on equity of -189.69%.

Oragenics has a consensus price target of --, signalling upside risk potential of 24523.8%. On the other hand Alaunos Therapeutics has an analysts' consensus of -- which suggests that it could grow by 10436.3%. Given that Oragenics has higher upside potential than Alaunos Therapeutics, analysts believe Oragenics is more attractive than Alaunos Therapeutics.

Oragenics has a beta of 0.434, which suggesting that the stock is 56.551% less volatile than S&P 500. In comparison Alaunos Therapeutics has a beta of -0.444, suggesting its less volatile than the S&P 500 by 144.433%.

Oragenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alaunos Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics pays -- of its earnings as a dividend. Alaunos Therapeutics pays out -- of its earnings as a dividend.

Oragenics quarterly revenues are --, which are smaller than Alaunos Therapeutics quarterly revenues of $4K. Oragenics's net income of -$2.5M is lower than Alaunos Therapeutics's net income of -$1.1M. Notably, Oragenics's price-to-earnings ratio is -- while Alaunos Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics is 1.44x versus -- for Alaunos Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.